about
Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.Management of myelofibrosis: JAK inhibition and beyond.Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment.3,6-Dihydroxyflavone regulates microRNA-34a through DNA methylation.Reactive granulomatous dermatitis presenting as subcutaneous nodules and cords in a patient with advanced myelodysplastic syndrome.Immune checkpoint molecules in acute myeloid leukaemia: managing the double-edged sword.Low-dose decitabine enhances chidamide-induced apoptosis in adult acute lymphoblast leukemia, especially for p16-deleted patients through DNA damage.CD82 hypomethylation is essential for tuberculosis pathogenesis via regulation of RUNX1-Rab5/22.The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma.Targeting Raf Kinase Inhibitory Protein Regulation and FunctionEpigenetics and Malaria Susceptibility/Protection: A Missing Piece of the Puzzle
P2860
Q30235355-0A85880D-0397-4807-B741-41EFC0108E01Q38651923-BE958894-E563-40A8-985B-533C612DB4AAQ38664735-0B477311-4567-4333-8FDE-999B5C651ADEQ38758162-8F6B632F-41A6-405E-BDC3-FE0856581950Q39232415-0FDDCBE1-6D5D-491F-B236-3D6B84134D1CQ41573313-4162A685-7693-4862-8D37-DAE8457C1BD8Q41613271-083CC302-25D8-456B-98DC-659A261B5878Q48216078-34C53AFC-84C3-4C89-8943-0FF1732145E1Q48273861-F3BE30AE-D8CA-49FA-B5D2-4FF6AD59DFCDQ51835906-9AAA80C7-88CE-4BBE-B63D-D935D442D1C6Q55436214-A51E8C33-7084-487D-A824-7316B0932262Q55519853-E8F15718-E98B-4982-9864-99E1155BA72BQ58764292-844428A7-0999-46AA-BF60-A403D3CE79B9Q58801166-6F5E949C-F238-44A7-B1A6-D4A576B306FD
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Epigenetics in Cancer: A Hematological Perspective
@ast
Epigenetics in Cancer: A Hematological Perspective
@en
Epigenetics in Cancer: A Hematological Perspective
@nl
type
label
Epigenetics in Cancer: A Hematological Perspective
@ast
Epigenetics in Cancer: A Hematological Perspective
@en
Epigenetics in Cancer: A Hematological Perspective
@nl
prefLabel
Epigenetics in Cancer: A Hematological Perspective
@ast
Epigenetics in Cancer: A Hematological Perspective
@en
Epigenetics in Cancer: A Hematological Perspective
@nl
P2093
P2860
P3181
P1433
P1476
Epigenetics in Cancer: A Hematological Perspective
@en
P2093
Amer M Zeidan
Maximilian Stahl
Tae Kon Kim
Thomas Prebet
P2860
P304
P3181
P356
10.1371/JOURNAL.PGEN.1006193
P407
P5008
P577
2016-10-01T00:00:00Z
2016-10-10T00:00:00Z